Barclays lowered the firm’s price target on Beam Therapeutics to $31 from $33 and keeps an Equal Weight rating on the shares. The company’s Q2 highlighted development progress, and the company reiterated its cash position of $1.0B and runway into 2027, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
- CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
- Beam Therapeutics initiated with a Buy at H.C. Wainwright
- Cathie Wood’s ARK Investment buys 60K shares of Beam Therapeutics today
- Cathie Wood’s ARK Investment buys 160K shares of Beam Therapeutics today
Questions or Comments about the article? Write to editor@tipranks.com